AxoGen saw the highest growth of 2.99% in patent filings and 1.74% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 2.99% and grants by 1.74%. GlobalData’s DataBook provides a comprehensive analysis of AxoGen‘s patent filings and grants. Buy the databook here.
AxoGen has been focused on protecting inventions in United States(US) with nine publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 33% filings and 18% grants. The United States(US), European Patent Office(EPO), Australia(AU), and Israel(IL) patent Office are among the top ten patent offices where AxoGen is filings its patents. Among the top granted patent authorities, AxoGen has 18% of its grants in United States(US), 18% in European Patent Office(EPO) and 18% in Israel(IL).
AbbVie and ROKIT could be the strongest competitors for AxoGen
In terms of grant share, AxoGen stands first among its competitors followed by AbbVie and ROKIT.
Patents related to cell & gene therapy lead AxoGen's portfolio
AxoGen has the highest number of patents in cell & gene therapy. For cell & gene therapy, nearly 100% of patents were filed and 100% of patents were granted in Q2 2024.
Petrochemicals related patents lead AxoGen portfolio followed by general surgery devices, and image management
AxoGen has highest number of patents in petrochemicals followed by general surgery devices, image management, packaging, and medical device. For petrochemicals, nearly 41% of patents were filed and 38% of patents were granted in Q2 2024.
For comprehensive analysis of AxoGen's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.